CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas
SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milestone payment to CytomX. CytomX and Astellas are collaborating on multiple conditionally activated TCB programs with CytomX eligible to receive additional future preclinical, clinical and commercial milestones. CytomX retains a cost share and co-commercialization option on a select number of targets.
- SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. today announced the achievement of a second clinical candidate nomination under the companies’ TCB collaboration with Astellas, triggering a $5 million milestone payment to CytomX.
- CytomX and Astellas are collaborating on multiple conditionally activated TCB programs with CytomX eligible to receive additional future preclinical, clinical and commercial milestones.
- CytomX retains a cost share and co-commercialization option on a select number of targets.
- “The achievement of clinical candidate nomination for the second Probody® TCB program in our broad collaboration with Astellas underscores our capabilities in the exciting field of conditionally activated, masked T-cell engaging bispecifics.